About us
Pioneering dry powder
inhalation products
We accelerate access to innovative inhalation medicines
As the global pharmaceutical industry seeks more effective treatments, Iconovo pushes the boundaries of what is achievable with inhaled therapies. Our integrated solutions, where the inhaler and dry powder formulation are optimized together, often provide a superior administration form. This benefits patients not only in respiratory care but in any therapeutic area where inhalation offers a smarter alternative to tablets or injections.
Based in Sweden, Iconovo is a leading expert in developing and commercializing advanced inhalation platforms and medicines. Our portfolio of patented inhalers creates significant commercial opportunities for both new value-adding pharmaceuticals and cost-effective generic medicines. With a robust IP portfolio and an extensive inhalation-based product pipeline, we are a trusted partner in the industry. Iconovo is listed on Nasdaq First North Growth Market (ICO).
Global health through Innovative Inhalation Medicine.
We accelerate access to innovative inhalation medicines, across therapy areas, for the benefits of patients and healthcare globally.
Unlocking the full potential of medicine
Iconovo transforms treatments into accessible inhalation therapies, driven by the life-changing advantages they bring to patients and the efficiency they offer to healthcare systems. By seamlessly integrating advanced inhalers with precise dry powder formulations, Iconovo produces therapies that are not only easier to use than injections or tablets, but often more effective. With decades of knowledge and patented technology platforms, Iconovo bridges the gap between complex science and commercial success. This redefines the industry – creating opportunities across the full spectrum of inhaled therapies.
Quick facts
A leading company in inhaled medicine based in Lund, Sweden
Iconovo is a leading Swedish company developing new inhaled medicinal products, offering innovative and effective inhalation platforms to the international pharmaceutical industry. The company has several types of patented inhalers that can create significant commercial opportunities for the development of both new pharmaceuticals and generic medicines. Iconovo is a well-established company with patent families and an extensive product pipeline, and its strategy is focused on three core areas: contract development, license agreements, and Nordic drug sales. Iconovo is listed on Nasdaq First North Growth Market under the ticker ICO.
Our business model
Iconovo develops inhaler platforms at its own risk, with patent protection sought for all unique designs. Additionally, we usually advance suitable formulations and drug candidates up to pre-clinical PoC (Proof of Concept) or pilot PK (Pharmacokinetic) studies, before seeking partnerships for late-stage development and commercialization.
Revenue is primarily generated through upfront and milestone payments from partners during development, followed by royalties once the product reaches the market. For interchangeable generic products, Iconovo generally retains rights for direct sales in the Nordics, as well as the mandate to manufacture and supply the inhalers. This arrangement offers a practical and economic solution for partners while providing a source of continuous income for Iconovo.
Patient focus
Therapy areas
Iconovo offers smart and reliable products that help people with respiratory and other diseases manage their conditions and improve their health. While inhaled medicines are historically mainly associated with asthma and COPD, they can be applied in any therapy area to replace injections with a more patient-friendly administration form. Currently, Iconovo’s active projects outside of the respiratory area include for example:
● Obesity (semaglutide)
● Vaccination
● Post partum hemorrhage (oxytocin)
The lung is a particularly effective route of administration for peptides and larger molecules, as these are otherwise extensively degraded in the gut. An added benefit of Dry Powder Inhalation is that the formulation is often less sensitive to high temperatures and temperature variations, eliminating the need for refrigeration in transport and storage.
Our history
Iconovo was founded in 2013 by persons with strong background and experience in inhalation product development, entrepreneurship and industrial design. In the beginning, the Iconovo team developed a large number of device concepts and prototypes. Today the company portfolio covers a full family of inhalation products comprising both inhalation devices and dry powder formulations.
Image: Dr. Orest Lastow, founder of Iconovo